Crizanlizumab in Sickle Cell Disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Novel Strategies for the Treatment of COVID-19.Drugs in R&D · 2022
   Article
2. Advances in the Management of Sickle Cell Disease: New Concepts and Future Horizons.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022
   Article
3. Adhesion molecules and cerebral microvascular hemodynamic abnormalities in sickle cell disease.Frontiers in neurology · 2022
   Article
4. Toxins · 2021
   Review
5. P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab.Journal of pain research · 2021
   Review
6. Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date.Journal of blood medicine · 2019
   Article

Corrections and comments

• Commented on by
  Crizanlizumab in Sickle Cell Disease.2017
• Comment on
  Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as